767 related articles for article (PubMed ID: 22385653)
1. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.
Ranganath SH; Levy O; Inamdar MS; Karp JM
Cell Stem Cell; 2012 Mar; 10(3):244-58. PubMed ID: 22385653
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stem Cell Secretome as an Emerging Cell-Free Alternative for Improving Wound Repair.
Ahangar P; Mills SJ; Cowin AJ
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987830
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome.
Harrell CR; Fellabaum C; Jovicic N; Djonov V; Arsenijevic N; Volarevic V
Cells; 2019 May; 8(5):. PubMed ID: 31100966
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the mesenchymal stem cell secretome for regenerative urology.
Sun DZ; Abelson B; Babbar P; Damaser MS
Nat Rev Urol; 2019 Jun; 16(6):363-375. PubMed ID: 30923338
[TBL] [Abstract][Full Text] [Related]
5. Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease.
Teixeira FG; Carvalho MM; Panchalingam KM; Rodrigues AJ; Mendes-Pinheiro B; Anjo S; Manadas B; Behie LA; Sousa N; Salgado AJ
Stem Cells Transl Med; 2017 Feb; 6(2):634-646. PubMed ID: 28191785
[TBL] [Abstract][Full Text] [Related]
6. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations.
Psaltis PJ; Paton S; See F; Arthur A; Martin S; Itescu S; Worthley SG; Gronthos S; Zannettino AC
J Cell Physiol; 2010 May; 223(2):530-40. PubMed ID: 20162565
[TBL] [Abstract][Full Text] [Related]
7. Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes.
Isildar B; Ozkan S; Sahin H; Ercin M; Gezginci-Oktayoglu S; Koyuturk M
Int Immunopharmacol; 2024 Mar; 129():111662. PubMed ID: 38340421
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of heat-inactivated, secretome-deficient MSC and metabolically active MSC in sepsis and allogenic heart transplantation.
Weiss ARR; Lee O; Eggenhofer E; Geissler E; Korevaar SS; Soeder Y; Schlitt HJ; Geissler EK; Hoogduijn MJ; Dahlke MH
Stem Cells; 2020 Jun; 38(6):797-807. PubMed ID: 32101344
[TBL] [Abstract][Full Text] [Related]
9. Paracrine Effects of Mesenchymal Stem Cells in Ischemic Stroke: Opportunities and Challenges.
Asgari Taei A; Khodabakhsh P; Nasoohi S; Farahmandfar M; Dargahi L
Mol Neurobiol; 2022 Oct; 59(10):6281-6306. PubMed ID: 35922728
[TBL] [Abstract][Full Text] [Related]
10. The effect of Trimetazidine and Diazoxide on immunomodulatory activity of human embryonic stem cell-derived mesenchymal stem cell secretome.
Jahandideh S; Maghsood F; Ghahhari NM; Lotfinia M; Mohammadi M; Johari B; Kadivar M
Tissue Cell; 2017 Oct; 49(5):597-602. PubMed ID: 28843336
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning.
Ferreira JR; Teixeira GQ; Santos SG; Barbosa MA; Almeida-Porada G; Gonçalves RM
Front Immunol; 2018; 9():2837. PubMed ID: 30564236
[TBL] [Abstract][Full Text] [Related]
12. Regenerative Potential of Mesenchymal Stem Cells' (MSCs) Secretome for Liver Fibrosis Therapies.
Nazarie Ignat SR; Gharbia S; Hermenean A; Dinescu S; Costache M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948088
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine.
Miceli V; Bulati M; Iannolo G; Zito G; Gallo A; Conaldi PG
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466583
[TBL] [Abstract][Full Text] [Related]
14. Pretreated Mesenchymal Stem Cells and Their Secretome: Enhanced Immunotherapeutic Strategies.
Su Y; Xu C; Cheng W; Zhao Y; Sui L; Zhao Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674790
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases.
Guo Y; Yu Y; Hu S; Chen Y; Shen Z
Cell Death Dis; 2020 May; 11(5):349. PubMed ID: 32393744
[TBL] [Abstract][Full Text] [Related]
16. The Secretome Derived From 3D-Cultured Umbilical Cord Tissue MSCs Counteracts Manifestations Typifying Rheumatoid Arthritis.
Miranda JP; Camões SP; Gaspar MM; Rodrigues JS; Carvalheiro M; Bárcia RN; Cruz P; Cruz H; Simões S; Santos JM
Front Immunol; 2019; 10():18. PubMed ID: 30804924
[TBL] [Abstract][Full Text] [Related]
17. Insights into the Effects of Mesenchymal Stem Cell-Derived Secretome in Parkinson's Disease.
d'Angelo M; Cimini A; Castelli V
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718092
[TBL] [Abstract][Full Text] [Related]
18. Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications.
Eleuteri S; Fierabracci A
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31533317
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke.
Cunningham CJ; Redondo-Castro E; Allan SM
J Cereb Blood Flow Metab; 2018 Aug; 38(8):1276-1292. PubMed ID: 29768965
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cell secretome for traumatic brain injury: Focus on immunomodulatory action.
Pischiutta F; Caruso E; Cavaleiro H; Salgado AJ; Loane DJ; Zanier ER
Exp Neurol; 2022 Nov; 357():114199. PubMed ID: 35952763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
